Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Sodium nitrite + sildenafil** is a combination of two drugs: sodium nitrite, an inorganic compound used medically as an antidote or vasodilator, and sildenafil, a phosphodiesterase type 5 inhibitor (PDE5 inhibitor) primarily used for erectile dysfunction and pulmonary arterial hypertension. Both drugs act as vasodilators but through distinct mechanisms. Sodium nitrite acts as a nitric oxide donor, increasing nitric oxide in the blood and relaxing vascular smooth muscle via the nitric oxide–cGMP pathway. Sildenafil inhibits phosphodiesterase type 5, prolonging cGMP activity and enhancing vasodilation. When used in combination, these drugs can have additive effects on vasodilation, leading to significant lowering of blood pressure. Due to this synergy, co-administration is generally contraindicated, as it can result in dangerously low blood pressure and cardiovascular risk. Documented uses include experimental settings for acute pulmonary hypertension and pulmonary embolism, but the combination is not approved for routine clinical use and is associated with serious safety warnings.[1][3][4][5][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium nitrite + sildenafil.